NovaDigm blends modern telemedicine with a focus on longevity and wellness, while continuing to report on cutting-edge advancements in biotechnology and therapeutics.
Location: United States, North Dakota, Grand Forks
Employees: 11-50
Founded date: 2005
Investors 1
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
Mentions in press and media 4
| Date | Title | Description |
| 04.10.2013 | $14M round for ‘cross-kingdom vaccine’ maker will fund trials in prevention of yeast infections | The vaccine contains a recombinant form of Als3, a protein found on the surface of Candida albicans which helps it bind to and invade human endothelial cells. The synthetic version of the protein used in the vaccine is produced by the ferme... |
| 15.05.2012 | ‘Cross-kingdom’ vaccine may protect against fungal and bacterial infections | NovaDigm just released positive data for a phase 1 trial of the vaccine, which demonstrated that a single dose was safe, well tolerated and induced strong antibody and T-cell immune response in healthy humans. The company’s next study, slat... |
| - | ‘Cross-kingdom’ vaccine may protect against fungal and bacterial infections | A clinical-stage pharmaceutical company with a vaccine it says uses a single antigen to protect against both fungal and bacterial infections is looking for a series B round to fund phase 2 trials for hospital-associated infection and women’... |
| - | $14M round for ‘cross-kingdom vaccine’ maker will fund trials in prevention of yeast infections | Whereas most vaccines under development are designed to protect against one kind of pathogen, NovaDigm Therapeutics thinks a vaccine it’s developing could protect against certain fungal and bacterial infections caused by several species of ... |